Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 6/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400378 | 0.90 | TRPA1 (0.44) | TRPA1MAPTALOX15PRKCA | |
| SCHEMBL25273347 | 0.89 | TRPA1 (0.43) | TRPA1MAPTALOX15PRKCA | |
| SCHEMBL25273718 | 0.86 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL25270009 | 0.83 | TRPA1 (0.41) | TRPA1MAPTALOX15 | |
| SCHEMBL25218585 | 0.83 | TRPA1 (0.41) | TRPA1MAPTALOX15 | |
| SCHEMBL25221473 | 0.83 | TRPA1 (0.41) | TRPA1MAPTALOX15 | |
| SCHEMBL25218443 | 0.83 | TRPA1 (0.41) | TRPA1MAPTALOX15 | |
| SCHEMBL25226617 | 0.83 | TRPA1 (0.41) | TRPA1MAPTALOX15 | |
| SCHEMBL25226789 | 0.81 | TRPA1 (0.40) | TRPA1 | |
| SCHEMBL25223689 | 0.81 | TRPA1 (0.40) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1839653-B9 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-2196200-A1 | Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes | Meiji Dairies Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
| EP-1839653-B1 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | disclosed |
| EP-1839653-A1 | THERAPEUTIC AGENT FOR SENSORY ABNORMALITY | Meiji Dairies Corporation (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7166642-B1 | Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases | MEIJI DAIRIES CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1150667-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | MEIJI DAIRIES CORP (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1003706-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PROD CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6228893-B1 | TREATING DEMENTIA | MEIJI MILK PRODUCTS CO., LTD. (JP) | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | CPT1B, CHRM1, ADRA1D | TRPA1 2967/4885ALDH1A1 416/4885LMNA 785/4885 |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | PMP22, NGF, HRH1 | TRPA1 13/4885ALDH1A1 200/4885LMNA 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.